Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

April 10, 2025

Primary Completion Date

January 25, 2026

Study Completion Date

January 25, 2026

Conditions
Inflammatory Disorder of Immune SystemSpondylitis, AnkylosingArthritis, RheumatoidArthritis, PsoriaticInflammatory Bowel DiseasesSjogren's SyndromeLupus Erythematosus, Systemic
Interventions
OTHER

1 blood sample, 40 mL (collection during a blood test, part of the standard of care for this disease)

Mononuclear and polynuclear peripheral blood cells from subjects suffering from IMID will be exposed in vitro to different inflammatory inducers with and without the concomitant addition of at least 4 different pCB extracts spectrum complete (full spectrum) including a dominant CBD extract and low in THC (\<0.2%), 1 dominant THC extract, 1 balanced THC/CBD extract and 1 dominant CBG extract. The same analyzes will be carried out in the presence of a recognized anti-inflammatory (for example hydrocortisone or dexamethasone) which will thus be used as a positive control.

Trial Locations (1)

45067

RECRUITING

CHU d'ORLEANS, Orléans

All Listed Sponsors
lead

Centre Hospitalier Régional d'Orléans

OTHER